State of Affairs with Respect to Canadian Cost Studies
Despite the importance of costing work, Canadian oncologists, health services researchers, and policymakers have long experienced difficulty publishing Canadian analyses. Review comments returned for Canadian burden-of-illness and health services research manuscripts have included statements such as these:
■ "The scientific impact of this study is limited due to the specificity of the data to Canada." ■ "Why should one even care about the use of care services in Canada?"
Furthermore, journals have commented that there is a "lack of alternative journals that may publish Canadianspecific models." Although studies comparing Canadian with American or European cost data (or both) have less difficulty being published in high-impact international journals, studies solely using Canadian cost data are typically left out in the cold. Good-quality work therefore either goes unpublished or published in less prestigious journals.
Where Are We Today?
Canada has some of the most robust, representative, and comprehensive health care data. Where, then, should Canadian researchers publish burden-of-illness studies, health services research, and models using Canadian cost data?
Current Oncology and the Canadian Partnership Against Cancer have partnered to create a supplement in which researchers can publish quality work using Canadian cost data. In July 2015, Current Oncology put out a call for papers. In particular, submissions to the supplement could include studies concerning any cancer site and could use regional, provincial, or national data sources to evaluate any of these themes: burden-of-illness studies; costs of interventions, programs, and policies; applied costing studies; direct costs borne by patients or other payers; indirect costs reflecting lost earnings or productivity; population health modelling studies; and studies adapting models to the Canadian context. All studies using data from clinical, administrative, or survey sources to take a patient, health care system, or societal perspective were considered.
The successful launch attracted enormous interest from researchers. Of twenty-five submissions received, twenty-two went out for review. Of those twenty-two, nineteen were judged appropriate for the supplement, and in the end, purely because of space limitations and a quest for diversity, eight were ranked for inclusion.
The manuscripts in the present supplement use a wide array of methods and Canadian data sources to deal with various disease sites and relevant issues in cancer care. In particular, they include studies relating to breast cancer (analysis of the cost implications of unwarranted imaging of patients, and an economic evaluation of a novel technology) and cervical cancer (estimation of utilization and costs, and use of a simulation model to evaluate cytology compared with primary human papillomavirus dna screening). Other studies focus on the estimation of drug and pathology cost avoidance in clinical trials and the cost trajectories of cancer patients over time. Finally, two studies provide an overview of the trends in costs for systemic therapy, home nursing, and hospitalizations for end-of-life care across the country.
We sincerely thank Current Oncology for providing a home for this important work. In addition, we gratefully acknowledge the Canadian Partnership Against Cancer for supporting this initiative. Lastly, we thank all the authors who submitted their manuscripts for this supplement. Given the importance of this work and the many submissions received, we recognize the need for a future supplement. We are hopeful that another will appear in the near future.
